Cordyceps Sunshine Biotech Holdings Co Ltd Financials
This page shows Cordyceps Sunshine Biotech Holdings Co Ltd (RAJAF) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Positive operating cash flow is being consumed by heavy reinvestment, while thin liquidity leaves little room for missteps.
FY2024 produced operating cash flow of$312K despite a net loss of-$226K , showing that reported earnings were pulled down by large non-cash charges rather than a full cash collapse. That pattern was already visible in FY2023, and with depreciation and amortization at$407K against capex of$349K , the business looks asset-heavy: cash comes in from operations, then gets recycled into maintaining the asset base.
Revenue reached
The balance sheet carries negative equity of
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Cordyceps Sunshine Biotech Holdings Co Ltd's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Cordyceps Sunshine Biotech Holdings Co Ltd has an operating margin of -11.3%, meaning the company retains $-11 of operating profit per $100 of revenue. This below-average margin results in a low score of 11/100, suggesting thin profitability after operating expenses. This is up from -14.7% the prior year.
Cordyceps Sunshine Biotech Holdings Co Ltd's revenue declined 0.6% year-over-year, from $1.3M to $1.2M. This contraction results in a growth score of 65/100.
Cordyceps Sunshine Biotech Holdings Co Ltd's current ratio of 0.19 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.
Cordyceps Sunshine Biotech Holdings Co Ltd passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Cordyceps Sunshine Biotech Holdings Co Ltd generates $0.23 in operating cash flow (-$36K OCF vs -$155K net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Cordyceps Sunshine Biotech Holdings Co Ltd generated $1.2M in revenue in fiscal year 2025. This represents a decrease of 0.6% from the prior year.
Cordyceps Sunshine Biotech Holdings Co Ltd's EBITDA was -$6K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 102.6% from the prior year.
Cordyceps Sunshine Biotech Holdings Co Ltd reported -$155K in net income in fiscal year 2025. This represents an increase of 31.6% from the prior year.
Cordyceps Sunshine Biotech Holdings Co Ltd earned $0.00 per diluted share (EPS) in fiscal year 2025.
Cash & Balance Sheet
Cordyceps Sunshine Biotech Holdings Co Ltd held $3K in cash against $0 in long-term debt as of fiscal year 2025.
Cordyceps Sunshine Biotech Holdings Co Ltd had 111M shares outstanding in fiscal year 2025. This represents an increase of 0.0% from the prior year.
Margins & Returns
Cordyceps Sunshine Biotech Holdings Co Ltd's gross margin was 61.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 11.2 percentage points from the prior year.
Cordyceps Sunshine Biotech Holdings Co Ltd's operating margin was -11.3% in fiscal year 2025, reflecting core business profitability. This is up 3.3 percentage points from the prior year.
Cordyceps Sunshine Biotech Holdings Co Ltd's net profit margin was -12.4% in fiscal year 2025, showing the share of revenue converted to profit. This is up 5.6 percentage points from the prior year.
Capital Allocation
RAJAF Income Statement
| Metric | Q4'25 | Q4'24 | Q4'23 | Q3'23 | Q4'22 | Q4'21 | Q4'20 |
|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Income | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
RAJAF Balance Sheet
| Metric | Q4'25 | Q4'24 | Q4'23 | Q3'23 | Q4'22 | Q4'21 | Q4'20 |
|---|---|---|---|---|---|---|---|
| Total Assets | $4.7M+0.7% | $4.6M+37.9% | $3.4M+86.4% | $1.8M-14.6% | $2.1M-35.5% | $3.3M+15.5% | $2.8M |
| Current Assets | $998K+65.8% | $602K+83.9% | $327K+527.6% | $52K-89.6% | $502K-55.6% | $1.1M+19.2% | $949K |
| Cash & Equivalents | $3K-91.4% | $37K+61.4% | $23K+36.6% | $17K+155.1% | $7K-93.4% | $100K+33806.1% | $294 |
| Inventory | $674K | N/A | N/A | $4K-98.6% | $314K-34.7% | $480K-29.9% | $685K |
| Accounts Receivable | N/A | $305 | N/A | N/A | $150K-58.2% | $358K | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $5.2M+3.9% | $5.0M+42.7% | $3.5M+76.9% | $2.0M-35.2% | $3.1M-13.6% | $3.5M+24.7% | $2.8M |
| Current Liabilities | $5.2M+4.1% | $5.0M+68.1% | $3.0M+102.4% | $1.5M-41.9% | $2.5M-13.7% | $2.9M+21.1% | $2.4M |
| Long-Term Debt | N/A | N/A | $431K+325.4% | $101K-75.5% | $414K | N/A | N/A |
| Total Equity | -$535K-42.3% | -$376K-147.4% | -$152K+17.0% | -$183K+80.8% | -$951K-244.9% | -$276K-2052.8% | -$13K |
| Retained Earnings | -$854K-22.1% | -$699K-47.8% | -$473K+0.9% | -$477K+61.0% | -$1.2M-142.7% | -$504K-3643.6% | -$13K |
RAJAF Cash Flow Statement
| Metric | Q4'25 | Q4'24 | Q4'23 | Q3'23 | Q4'22 | Q4'21 | Q4'20 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | N/A | N/A | -$1.2M | N/A | -$111K | N/A | N/A |
| Capital Expenditures | N/A | N/A | -$1.2M | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | -$2.5M | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | $1.2M | N/A | -$1K | N/A | N/A |
| Financing Cash Flow | N/A | N/A | $48K | N/A | $7K | N/A | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
RAJAF Financial Ratios
| Metric | Q4'25 | Q4'24 | Q4'23 | Q3'23 | Q4'22 | Q4'21 | Q4'20 |
|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | 0.19+0.1 | 0.12+0.0 | 0.11+0.1 | 0.04-0.2 | 0.20-0.2 | 0.390.0 | 0.39 |
| Debt-to-Equity | -9.71+3.6 | -13.31-10.5 | -2.84-2.3 | -0.55-0.1 | -0.44+12.4 | -12.83+208.7 | -221.55 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$535K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.19), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Frequently Asked Questions
What is Cordyceps Sunshine Biotech Holdings Co Ltd's annual revenue?
Cordyceps Sunshine Biotech Holdings Co Ltd (RAJAF) reported $1.2M in total revenue for fiscal year 2025. This represents a -0.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Cordyceps Sunshine Biotech Holdings Co Ltd's revenue growing?
Cordyceps Sunshine Biotech Holdings Co Ltd (RAJAF) revenue declined by 0.6% year-over-year, from $1.3M to $1.2M in fiscal year 2025.
Is Cordyceps Sunshine Biotech Holdings Co Ltd profitable?
No, Cordyceps Sunshine Biotech Holdings Co Ltd (RAJAF) reported a net income of -$155K in fiscal year 2025, with a net profit margin of -12.4%.
What is Cordyceps Sunshine Biotech Holdings Co Ltd's EBITDA?
Cordyceps Sunshine Biotech Holdings Co Ltd (RAJAF) had EBITDA of -$6K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Cordyceps Sunshine Biotech Holdings Co Ltd's gross margin?
Cordyceps Sunshine Biotech Holdings Co Ltd (RAJAF) had a gross margin of 61.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Cordyceps Sunshine Biotech Holdings Co Ltd's operating margin?
Cordyceps Sunshine Biotech Holdings Co Ltd (RAJAF) had an operating margin of -11.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Cordyceps Sunshine Biotech Holdings Co Ltd's net profit margin?
Cordyceps Sunshine Biotech Holdings Co Ltd (RAJAF) had a net profit margin of -12.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Cordyceps Sunshine Biotech Holdings Co Ltd's operating cash flow?
Cordyceps Sunshine Biotech Holdings Co Ltd (RAJAF) generated -$36K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Cordyceps Sunshine Biotech Holdings Co Ltd's total assets?
Cordyceps Sunshine Biotech Holdings Co Ltd (RAJAF) had $4.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What is Cordyceps Sunshine Biotech Holdings Co Ltd's current ratio?
Cordyceps Sunshine Biotech Holdings Co Ltd (RAJAF) had a current ratio of 0.19 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Cordyceps Sunshine Biotech Holdings Co Ltd's debt-to-equity ratio?
Cordyceps Sunshine Biotech Holdings Co Ltd (RAJAF) had a debt-to-equity ratio of -9.71 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Cordyceps Sunshine Biotech Holdings Co Ltd's return on assets (ROA)?
Cordyceps Sunshine Biotech Holdings Co Ltd (RAJAF) had a return on assets of -3.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Cordyceps Sunshine Biotech Holdings Co Ltd's cash runway?
Based on fiscal year 2025 data, Cordyceps Sunshine Biotech Holdings Co Ltd (RAJAF) had $3K in cash against an annual operating cash burn of $36K. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Cordyceps Sunshine Biotech Holdings Co Ltd's debt-to-equity ratio negative or unusual?
Cordyceps Sunshine Biotech Holdings Co Ltd (RAJAF) has negative shareholder equity of -$535K as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Cordyceps Sunshine Biotech Holdings Co Ltd's Piotroski F-Score?
Cordyceps Sunshine Biotech Holdings Co Ltd (RAJAF) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Cordyceps Sunshine Biotech Holdings Co Ltd's earnings high quality?
Cordyceps Sunshine Biotech Holdings Co Ltd (RAJAF) has an earnings quality ratio of 0.23x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Cordyceps Sunshine Biotech Holdings Co Ltd?
Cordyceps Sunshine Biotech Holdings Co Ltd (RAJAF) scores 17 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.